Aurobindo to Expand with USD 175M Biologics Unit Investment for MSD

Aurobindo Pharma has announced a major expansion through its biologics arm TheraNym Biologics, committing USD 150–175 million biologic unit investment to build a new biologics drug substance facility as part of its growing partnership with Merck Sharp & Dohme (MSD).

This biologics unit investment marks a key step in strengthening its presence in high-value drug manufacturing. The planned facility, referred to as Unit 2, will be a greenfield project focused on producing complex biologic drug substances.

It will house advanced mammalian cell culture systems with a total bioreactor capacity of around 60,000 liters, along with modern purification capabilities. These systems are essential for manufacturing next-generation therapies used in areas such as oncology and autoimmune diseases.

Also Read: The Future of MedTech in India: Meeting Tier-2 and Tier-3 Needs

This move builds on an earlier agreement signed between TheraNym and MSD in 2024, under which the Indian firm will manufacture and supply biologic drug substances. The new investment expands that collaboration, positioning Aurobindo as a long-term manufacturing partner for global pharmaceutical companies.

The biologics unit investment reflects a broader shift in Aurobindo’s strategy as it moves beyond traditional generics into more complex and profitable biologics. Industry demand for biologic therapies continues to rise globally, making this a timely expansion.

The company said the facility will cater to both domestic and international markets, aligning with its goal to scale up contract development and manufacturing operations. With this project, Aurobindo is not only increasing capacity but also upgrading its technological capabilities.

This investment signals a clear intent to compete in the global biologics space, where precision, scale, and partnerships define success.